Science Explorer Back to mapMap
Discussion
Researcher · Institut Claudius Regaud · France

Thierry Lafont

Thierry Lafont publishes mostly in Oncology, Pathology and Forensic Medicine and Molecular Biology, on topics such as Chemotherapy-induced organ toxicity mitigation, Cancer Treatment and Pharmacology and Cancer therapeutics and mechanisms.

OpenAlex
World rank
#5,116,997
of 7,710,434 ranked researchers
Rank in France
#216,021
of 324,115
Works
29
Citations
772
Citations per work
26.6
h-index
17
i10-index 20Top 30% in Oncology
Thierry Lafont

What does Thierry Lafont research?

Thierry Lafont's work is mostly in Medicine (44%), Biochemistry, Genetics and Molecular Biology (8%), Pharmacology, Toxicology and Pharmaceutics (5%).

Health Sciences: 13 works · 43.5% of their workMedicine: 13 works · 43.5% of their workOncology: 6 works · 19.7% of their workPathology and Forensic Medicine: 4 works · 13.2% of their workHematology: 2 works · 5.3% of their workPulmonary and Respiratory Medicine: 2 works · 5.3% of their workEverything else: 13 works · 43.3% of their workLife Sciences: 4 works · 13.2% of their workBiochemistry, Genetics and Molecular Biology: 2 works · 7.9% of their workMolecular Biology: 2 works · 7.9% of their workPharmacology, Toxicology and Pharmaceutics: 2 works · 5.3% of their workPharmacology: 2 works · 5.3% of their workTHEIR WORKThierry Lafont29works
Life Sciences13%Health Sciences44%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1343.5%
  2. Everything else1343.3%
    1. Biochemistry, Genetics and Molecular Biology27.9%
    2. Pharmacology, Toxicology and Pharmaceutics25.3%
  1. 1Oncology20% of their works
  2. 2Pathology and Forensic Medicine13% of their works
  3. 3Molecular Biology8% of their works
  4. 4Hematology5% of their works
  5. 5Pulmonary and Respiratory Medicine5% of their works
  6. 6Pharmacology5% of their works

Research topics

Which keywords describe Thierry Lafont's research?

The keywords of their largest research topics: Chemotherapy, Cisplatin, Nephrotoxicity, Chemotherapy-Induced Peripheral Neuropathy, Taxanes, DNA, Topoisomerases and BCR-ABL.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Chemotherapy163 topics
  2. Cisplatin91 topic
  3. Nephrotoxicity91 topic
  4. Chemotherapy-Induced Peripheral Neuropathy81 topic
  5. Taxanes81 topic
  6. DNA41 topic
  7. Topoisomerases41 topic
  8. BCR-ABL31 topic
  9. Cetuximab31 topic
  10. Cytochrome P45031 topic
  11. Imatinib31 topic
  12. KRAS Mutations31 topic
  13. Pharmacogenetics31 topic
  14. Chronic Hepatitis B21 topic
  15. Chronic Lymphocytic Leukemia21 topic
  16. Genomic Aberrations21 topic
  17. Hepatitis B Virus21 topic

Where does Thierry Lafont work?

Thierry Lafont's main affiliation in the publication record is Institut Claudius Regaud, France.

How many publications and citations does Thierry Lafont have?

OpenAlex counts 29 works and 772 citations for Thierry Lafont, an h-index of 17, ranking #5,116,997 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Thierry Lafont. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.